Your powerful AI agent
drug discovery tool
Revolutionize Drug Discovery Through the Intelligent Application of AI
AI-driven drug discovery (AIDD) integrates advanced machine learning and computational modeling to streamline therapeutic development
AIDD leverages deep learning and generative models to transform the drug discovery pipeline—including target identification, molecular design, and preclinical evaluation, uncovering novel therapeutics with greater speed, precision, and scalability.
At KumiChem™, we deliver a human-centered platform that amplifies the AIDD process through high-level automation and the seamless integration of expert knowledge with AI-driven innovation.
Applicablefor Everyone
Jumpstartwith Templates
FlexibleWorkflow Builder
KumiChem™ Automating AIDD workflows
Knowledge - Data - Models - People
No matter who you are in the world of drug discovery,
we're here to help you move faster, work smarter, and explore further
For Pharma Teams
Want to boost productivity on existing targets or explore brand-new ones? Our smart AI tools help you accomplish more, from target validation to ligand design, with speed and confidence.
For PI & University Labs
Bring the power of AI into your everyday research. Our tools are easy to adopt, flexible, and designed to supercharge your lab’s discovery workflows.
For Curious Minds & Learners
Just getting started or looking to stay up to date? Dive into the latest in drug discovery and AI with resources that make complex science simple and exciting.
Find the Best Solutions
Our system explores vast chemical and biological spaces, compares strategies, and recommends optimal paths — so you can make smarter decisions, faster.
Seamless & Scalable Workflows
Easily plug into your existing processes. Whether you're running a single experiment or scaling across projects, our platform flexes to your needs.
Collaboration-Ready
We've already begun working with real-world labs to co-create smarter solutions for delivering better medicines — faster. Now, we're looking for ambitious, like-minded partners to collaborate with and grow together.
Updates
Get the latest on our news, product updates, science blogs, and behind-the-scenes team stories — including milestone announcements, new features, and reflections from our journey
OCTOPUS Rack Design Contest Grant Prize Winner
Our UI/UX designer Ann Grishunova won the Grand Prize at the OCTOPUS (Osaka University Compute & sTOrage Platform Urging open Science) Rack Design Contest 2025 with her “Blossom” concept, symbolizing AI in innovation, growth, and the beauty of the world. View detailed
News №009
DLeader Joins Techstars Tokyo 2025 Class
DLeader has been selected to join Techstars, one of the world's leading startup accelerators, from a highly competitive pool of applicants spanning 120 countries, with an acceptance rate of less than 1%. View detailed
News №008
HVC Kyoto 2025
Our AI-driven drug discovery platform, KumiChem™, has been selected to participate in HVC Kyoto 2025, a leading healthcare venture conference in Japan that connects cutting-edge startups with investors, industry leaders, and global partners to accelerate innovation in life sciences. View detailed
News №007
Prof. Nakatani Joins as Scientific Advisor
We are honored to welcome Prof. Nakatani, a pioneer in small-molecule targeting of nucleic acids, as a scientific advisor. His groundbreaking research and passion for scientific innovation will play a pivotal role in shaping the next-gen drug discovery.
News №006
Ibaraki Tech Planter Talk
On February 8, 2025, at the Ibaraki Tech Planter Lightning Talk hosted by Leave a Nest, we presented the vision of our AI agent drug discovery platform, KumiChemTM. The event connected us with innovators, investors, and researchers eager to transform science through technology.
News №005
EXPO 2025 Selection
Our message, "Streamlining in-silico drug discovery workflows for a smarter, healthier future" was selected for Future Voyage at Expo 2025 Osaka, Kansai (Oct 3–7). View detailed
News №004
Prof. Mizuguchi Joins as Scientific Advisor
Spring 2024 marked the start of our collaboration with Prof. Mizuguchi at the University of Osaka, an internationally recognized leader in computational biology. His expertise in bioinformatics and AI-assisted drug design will help push the boundaries of in-silico research, opening new opportunities together.
News №003
Angel Investment
In June 2024, DLeader secured a ¥10 million angel investment from First Domino. This funding will support the development of our proprietary AI-driven drug discovery platform.
News №002
Official Launch
On April 12, 2024, DLeader officially launched in Osaka with Qingwen Chen as CEO. The company was founded to revolutionize AI-based drug discovery, aiming to support real-world therapies with intelligent automation.
News №001
Domain voices
User-friendly AI platform
The premise for conducting data analysis and using its results as guidelines or bases is the recognition of its validity. Validity primarily refers to "statistical significance," with criteria rooted in probability theory's Law of Large Numbers and Central Limit Theorem.
Additionally, data science's dimensionality reduction, forecasting, and classification clustering methods may also utilize highly advanced modern mathematical tools and cutting-edge theories, which contribute to the thriving field of data science and provide a solid scientific foundation for the platform.
Recognition of validity
Traditional drug development is typically a laborious and costly process with unavoidable ethical concerns regarding animal experiments and human trials. Employing AI can circumvent these issues and increase the efficiency of developing more effective and affordable drugs.
It is exciting to see that DLeader is providing this kind of user-friendly AI platform that enables researchers and companies to boost biomedical research and pharmaceutical development, ultimately benefiting educational purposes and public health.
DLeader's commitment to innovative drug development
Recent research in AI and data mining has significantly accelerated the development of technologies across various domains.
We're excited to see DLeader's commitment to innovative drug development, and we anticipate it becoming a pioneering leader in this field.
Revolutionize the industry
Developing a new platform for AI-based drug discovery could revolutionize the industry and lead to faster, more effective treatments.
I'm truly impressed by your courage to tackle such a challenging subject as a startup. I can't wait to see the impact your work will have on the healthcare industry.
The potential to significantly enhance patient
The integration of AI into medical research and clinical practice has the potential to significantly enhance patient care by providing faster, more accurate diagnoses and personalized treatment plans. Leveraging AI can optimize the use of medical data, leading to groundbreaking advancements.
We are inspired by Dleader's dedication to bringing these innovations into the healthcare field. Looking forward to seeing how your efforts will improve public health.
Frequently Asked Questions
What tasks can be performed with the KumiChem™ platform?
- QSAR Modeling: Predicting the biological activity and properties of small molecules to accelerate early-stage drug discovery.
- ASO (Antisense Oligonucleotide) Design: Supporting new drug modalities through AI-assisted sequence design and optimization.
- Idea Generation: Leveraging generative AI to explore novel chemical structures and therapeutic hypotheses.
- Data Curation: Cleaning, organizing, and validating chemical and biological datasets for more robust model training.
- Custom Model Training: Building tailored machine learning models using proprietary or domain-specific data to solve unique R&D challenges.
How is KumiChem™ different from other platforms?
Who should use KumiChem™ platform?
How can I get early access to KumiChem™?
